Evaluation of ctDNA in the Prediction of Response to Neoadjuvant Therapy and Prognosis in Locally Advanced Rectal Cancer Patients: A Prospective Study

• Tipo: Artigo em Revista Científica Internacional
• Data: 2023

Autores

Morais, M (Autor) Outra; Fonseca, T (Autor) FMUP; Melo-Pinto, D (Autor) Outra; Prieto, I (Autor) Outra; Vilares, AT (Autor) Outra; Duarte, AL (Autor) Outra; Leitao, P (Autor) Outra; Cirnes, L (Autor) Outra; Machado JC (Autor) FMUP; Carneiro, S (Autor) Outra

Revista

Título: Pharmaceuticals

Vol. 16

Página Final: 427

ISSN: 1424-8247

Editora: MDPI

Indexação

ISI Web of Knowledge - 0 Citações

Scopus

Outras Informações

ID Authenticus: P-00Y-34D

DOI: 10.3390/ph16030427

Abstract (EN): Watch and wait is becoming a common treatment option for patients with locally advanced rectal cancer (LARC) submitted to neoadjuvant treatment. However, currently, no clinical modality has an acceptable accuracy for predicting pathological complete response (pCR). The aim of this study was to assess the clinical utility of circulating tumor DNA (ctDNA) in predicting the response and prognosis in these patients. We prospectively enrolled a cohort of three Iberian centers between January 2020 and December 2021 and performed an analysis on the association of ctDNA with the main response outcomes and disease-free survival (DFS). The rate of pCR in the total sample was 15.3%. A total of 24 plasma samples from 18 patients were analyzed by next-generation sequencing. At baseline, mutations were detected in 38.9%, with the most common being TP53 and KRAS. Combination of either positive magnetic resonance imaging (MRI) extramural venous invasion (mrEMVI) and ctDNA increased the risk of poor response (p = 0.021). Also, patients with two mutations vs. those with fewer than two mutations had a worse DFS (p = 0.005). Although these results should be read carefully due to sample size, this study suggests that baseline ctDNA combined with mrEMVI could potentially help to predict the response and baseline ctDNA number of mutations might allow the discrimination of groups with different DFS. Further studies are needed to clarify the role of ctDNA as an independent tool in the selection and management of LARC patients.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 14